αv integrins mediate beta-amyloid induced inhibition of long-term potentiation

Neurobiology of Aging

Volumn 29, Issue 10, 2008, Pages 1485-1493

  Wang, Qinwen ^a   Klyubin, Igor ^a   Wright, Sarah ^b   Griswold Prenner, Irene ^b   Rowan, Michael J ^a   Anwyl, Roger ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ELAN PHARMACEUTICALS   (United States)

Author keywords

v integrin; Alzheimer's disease; Beta amyloid; Hippocampus; LTP

Indexed keywords

AMYLOID BETA PROTEIN; ANTIBODY; CD51 ANTIGEN; ECHISTATIN; FIBRONECTIN; SUPERFIBRONECTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; ELECTROPHYSIOLOGY; ENZYME INHIBITION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; DENTATE GYRUS; HIPPOCAMPUS; INTEGRIN ALPHAV; LIGANDS; LONG-TERM POTENTIATION; MALE; MICE; NERVE DEGENERATION; NEURAL INHIBITION; ORGAN CULTURE TECHNIQUES; PEPTIDES; RATS; RATS, WISTAR; SYNAPTIC TRANSMISSION;

EID: 49149112994     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.03.018     Document Type: Article

References (45)

1. Anderson J.L., Head S.I., and Morley JW. Synaptic plasticity in the dy2J mouse model of laminin (2-deficient congenital muscular dystrophy. Brain Res. 1042 (2005) 23-28
2. Anderson K.I., and Ferreira A. α1 Integrin activation: a link between β-amyloid deposition and neuronal death in aging hippocampal neurons. J. Neurosci. Res. 75 (2004) 688-697
3. Bahr B.A., Staubli U., Xiao P., Chun D., Ji Z.-X., Esteban E.T., and Lynch G. Pharmacological studies and the characterization of a candidate matrix receptor. J. Neurosci. 17 (1997) 1320-1329
4. Berg L., McKeel Jr. D.W., Miller J.P., Baty J., and Morris J.C. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch. Neurol. 50 (1993) 349-358
5. Chan C.-S., Weeber E.J., Kurup S., Sweatt D.J., and Davis R.L. Integrin requirement for hippocampal synaptic plasticity and spatial memory. J. Neurosci. 23 (2003) 7107-7116
6. Chang H.P., Lindbeg F.P., Wang H.L., Huang A.M., and Lee E.H.Y. Impaired memory retention and decreased long-term potentiation in integrin-associated protein-deficient mice. Learn. Memory 6 (1999) 448-457
7. Chun D., Gall C.M., Bi X., and Lynch G. Evidence that integrins contribute to multiple stages in the consolidation of long-term potentiation. Neuroscience 105 (2001) 815-829
8. Cullen W.K., Suh Y.H., Anwyl R., and Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8 (1997) 3213-3217
9. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
10. Davies C.A., Mann D.M., Sumpter P.Q., and Yates P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 78 (1987) 151-164
11. Deshpande A., Mina E., Glabe C., and Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 26 (2006) 6011-6018
12. Gan Z.R., Gould R.J., Jacobs J.W., Friedman P.A., and Polokoff M.A. Echistatin A potent platelet aggregation inhibitor from the venom of the viper Echis carinatus. J. Biol. Chem. 263 (1988) 19827-19832
13. Grotewiel M.S., Beck C.D., Wu C.F., and Greenspan R.J. Integrin-mediated short-term memory in Drosophila. Nature 18 (1998) 7847-7855
14. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
15. Humpries M.J. Integrin structure. Biochem. Soc. Trans. 28 (2000) 311-339
16. Klyubin I., Walsh D.M., Cullen W.K., Fadeeva J.V., Anwyl R., Selkoe D.J., and Rowan M.J. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci. 19 (2004) 2839-2846
17. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., and Rowan M.J. Amyloid α protein immunotherapy neutralizes Aα oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11 (2005) 556-561
18. Koenigsknecht J., and Landreth G. Microglial phagocytosis of fibrillar β-amyloid through a β1 integrin-dependent mechanism. J. Neurosci. 24 (2004) 9838-9846
19. Koenigsknecht-Talboo J., and Landreth G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25 (2005) 8240-8249
20. Kramer E.A., Bernard J.A., Gall C.M., and Lynch G. Alpha 3 integrin receptors contribute to the consolidation of long-term potentiation. Neuroscience 110 (2002) 29-39
21. Kramer E.A., Lin B., Rex C.S., Gall C.M., and Lynch G. Integrin-driven actin polymerisation consolidates long-term potentiation. PNAS 103 (2006) 5579-5584
22. Kumar C.C., Nie H., Rogers C.P., Malkowski M., Maxwell E., Catino J.J., and Armstrong J.J. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. J. Pharmacol. Exp. Ther. 283 (1997) 843-853
23. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. 95 (1998) 6448-6453
24. Lin B., Arai A.C., Lynch G., and Gall C.M. Integrins regulate NMDAR receptor-mediated synaptic currents. J. Neurophysiol. 89 (2003) 2874-2878
25. Morla A., Zhang Z., and Ruoslahti E. Superfibronectin is a functionally distinct form of fibronectin. Nature 367 (1994) 193-196
26. Nishimura S.L., Boylen K.P., Einheber S., Milner T.A., Ramos D.M., and Pytela R. Synaptic and glial localization of the integrin αvβ8 in mouse and rat brain. Brain Res. 791 (1998) 271-282
27. Pinkstaff J.K., Detterich J., Lynch G., and Gall C. Integrin subunit gene expression is regionally differentiated in adult brain. J. Neurosci. 19 (1999) 1541-1556
28. Raymond C.R., Ireland D.R., and Abraham W.C. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res. 968 (2003) 263-272
29. Rosenmund C., and Westbrook G.L. Calcium-induced actin depolymerization reduces NMDA channel activity. Neuron 10 (1993) 805-814
30. Sabo S., Lambert M.P., Kessey K., Wade W., Krafft G., and Klein W.L. Interaction of beta-amyloid peptides with integrins in a human nerve cell line. Neurosci. Lett. 184 (1995) 25-28
31. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
32. Sheppard D. Roles of αv integrins in vascular biology and pulmonary pathology. Curr. Opin. Cell Biol. 16 (2004) 552-557
33. Sheu J.R., Yen M.H., Kan Y.C., Hung W.C., Chang P.T., and Luk H.N. Inhibition of angiogenesis in itro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha (v) beta3 integrin monoclonal antibody. Biochim. Biophys. Acta 1336 (1997) 445-454
34. Small D.H., Mok S.S., and Bornstein J.C. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 8 (2002) 595-598
35. Stalder M., Deller T., Staufenbiel M., and Jucker M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol. Aging 22 (2001) 427-434
36. Staubli U., Vanderklish P.W., and Lynch G. An inhibitor of integrin receptor blocks LTP. Behav. Neural. Biol. 53 (1990) 1-5
37. Teter B., and Ashford J.W. Neuroplasticity in Alzheimer's disease. J. Neurosci. Res. 70 (2002) 402-437
38. Van Waes C., Enamorado-Ayala I., Hecht D., Sulica L., Chen Z., Batt D.G., and Mousa S. Effects of the novel alphav integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8. Int. J. Oncol. 16 (2000) 1189-1195
39. Verdier Y., Zarandi M., and Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 10 (2004) 229-248
40. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., and Shelanski M. Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13217-13221
41. Walsh D.M., Klyubuin I., Fadeeva J., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of the Alzheimer amyloid (-protein potently inhibit long-term potentiation in vivo. Nature 416 (2002) 535-539
42. Wang Q., Walsh D.M., Rowan M.J., Selkoe D.J., and Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24 (2004) 3370-3378
43. Wang Q., Rowan M.J., and Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 24 (2004) 6049-6056
44. Wang Q., Wu J., Rowan M.J., and Anwyl R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur. J. Neurosci. 22 (2005) 2827-2832
45. Wright S., Malinin N.L., Powell K.A., Yednock T., Rydel R.E., and Griswold-Prenner I. Alpha2beta1 and alphaVbeta1 integrin signaling pathways mediate amyloid-beta-induced neurotoxicity. Neurobiol. Aging. 28 (2007) 226-237